The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Mouse Anti-Plasmodium Species LDH Antibody (M301)

$376.65$945.11 excl. VAT

Mouse anti Plasmodium species Lactate dehydrogenase (LDH) (IgG1, clone M301). Suitable for use in ELISA and lateral flow applications.

Matched Pair

 

MOUSE ANTI-PLASMODIUM SPECIES LDH ANTIBODY (M301)

Mouse anti Plasmodium species LDH antibody (clone M301) recognises lactate dehydrogenase (LDH) from Plasmodium species. The antibody is suitable for ELISA and lateral flow applications. M301 (MAB12350) can be used as an antibody pair with M300 (MAB12349).

 

PRODUCT DETAILS – MOUSE ANTI-PLASMODIUM SPECIES LDH ANTIBODY (M301)

  • Mouse anti Plasmodium species LDH (IgG1, clone M301) monoclonal antibody recognises Plasmodium species lactate dehydrogenase.
  • Suitable for use in ELISA and lateral flow applications.
  • Purified by Protein A chromatography.  >90% purity by SDS-PAGE.
  • Presented in phosphate buffered saline, pH 7.3 with 0.05% sodium azide.

 

BACKGROUND

A quick and accurate diagnosis of malaria is essential prior to treatment to prevent progression to severe disease and to reduce the reservoir of parasites in the human population. Diagnosis of malaria is currently based on clinical symptoms, blood film for malaria parasites (BFMP), polymerase chain reaction (PCR) and rapid diagnostic test (RDT). Plasmodium lactate dehydrogenase (LDH) enzyme is essential for energy production by the parasite, and is considered to be a potential target for anti-malarial drugs. Plasmodium LDH has also been identified as a potential diagnostic marker for the detection of Plasmodium antigen in human blood. Plasmodium LDH enzyme has been used as a target antigen in the development of rapid diagnostic tests (RDTs) for malaria diagnosis.

Malaria is a globally widespread infectious disease caused by obligate intracellular protozoan parasites of the genus Plasmodium. Five different species of Plasmodium are known to cause disease in humans including P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Most cases of Malaria occur in African regions and the Americas. In African regions, P. falciparum causes the majority of malaria cases, whereas P. vivax is the predominant cause of malaria in regions of the Americas (WHO). Cases of malaria caused by P. ovale and P. malariae are uncommon or rare. Cases of malaria caused by P. knowlesi are common in Malaysia and are reported to be on the increase (Barber, BE).

Malaria is a mosquito-borne disease that is transmitted to humans through the bite of infected female mosquitoes of the Anopheles species. It may also be transmitted to individuals through the transfusion of contaminated blood, but this is rare. Many different species of Anopheles mosquitoes have been identified as vectors for malaria and the species can vary according to geographical location. The Anopheles mosquitoes, causing most cases of malaria, bite from dawn until dusk and lay their eggs in shallow water, which develop into larvae and then emerge as adults.

In uncomplicated cases, malaria can develop over a period of 7-18 days. The symptoms of malaria include fever, general malaise, nausea, chills, myalgia and headache. In cases of severe malaria clinical symptoms include confusion, acidosis, hypoglycaemia, anaemia, renal impairment and jaundice. If left untreated, cases of severe malaria can worsen leading to coma and death. The progression of the disease to severe malaria can depend on many factors including the species of the Plasmodium species involved, the age of the individual, immune status, correct diagnosis and availability of treatment (WHO).

 

REFERENCES

Product datasheet
Safety datasheet

Ambient